CD4 and sarcoma: To determine whether our findings were relevant in the context of non-TCR transgenic T cells, we evaluated the role of IL-2 in the acquisition of cytotoxic activity by CD4+ T cells in MCA205 sarcoma, which is known to respond to αCTLA-4 monotherapy.